He Song-Bing, Zhou Hao, Zhou Jian, Zhou Guo-Qiang, Han Tuo, Wan Dai-Wei, Gu Wen, Gao Lin, Zhang Yi, Xue Xiao-Feng, Zhang Li-Feng, Fei Min, Hu Shui-Qing, Yang Xiao-Dong, Zhu Xin-Guo, Wang Liang, Li De-Chun
Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China Department of General Surgery, the First Affiliated Hospital of Soochow University, Suzhou 215006, China
Department of General Surgery, the First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Exp Biol Med (Maywood). 2015 Apr;240(4):458-66. doi: 10.1177/1535370214542215. Epub 2014 Jul 8.
Epigenetic changes have been recently recognized as important in many human cancers. Enhancer of zeste homologue 2 (EZH2)gene has shown overexpression in various human cancers, consistent with a straightforward role of EZH2 as an oncogene, but its function in carcinogenesis is partly contradictory. The role of EZH2 in development of human colorectal cancer (CRC) has not yet been clarified. In present study, we observed up-regulation of EZH2 expression in tumor tissues from CRC patients [corrected]. The expression of EZH2 in CRC cell lines is consistent with the trend in cancer tissues using RT-PCR. We showed that TNM stage and lymph node metastasis in CRC patients are significantly correlated with EZH2 expression levels [corrected]. EZH2 level of transcription and protein was inhibited by small interfering RNA (siRNA). More importantly, EZH2-siRNA inhibited the proliferation and migration of SW620 cells while promoting their apoptosis, and inducing G0/G1 cell cycle arrest of CRC cells. Collectively, our results suggest that upregulated EZH2 expression may contribute to the progression of the patients with CRC. A comprehensive study of epigenetic mechanisms and the relevance of EZH2 in CRC is important for fully understanding this disease and as a basis for developing new treatment options in patients with CRC [corrected].
表观遗传变化最近被认为在许多人类癌症中起着重要作用。zeste同源物2增强子(EZH2)基因在多种人类癌症中均有过表达,这与EZH2作为癌基因的直接作用相一致,但其在致癌过程中的功能存在部分矛盾之处。EZH2在人类结直肠癌(CRC)发生发展中的作用尚未阐明。在本研究中,我们观察到CRC患者肿瘤组织中EZH2表达上调[已修正]。使用逆转录-聚合酶链反应(RT-PCR)检测发现,CRC细胞系中EZH2的表达与癌组织中的趋势一致。我们发现,CRC患者的TNM分期和淋巴结转移与EZH2表达水平显著相关[已修正]。小干扰RNA(siRNA)可抑制EZH2的转录水平和蛋白表达。更重要的是,EZH2-siRNA抑制了SW620细胞的增殖和迁移,同时促进其凋亡,并诱导CRC细胞发生G0/G1期细胞周期阻滞。总体而言,我们的结果表明,EZH2表达上调可能促进CRC患者病情进展。全面研究CRC的表观遗传机制以及EZH2的相关性,对于充分理解这种疾病以及作为开发CRC患者新治疗方案的基础具有重要意义[已修正]。